9780128052112

0128052112

9780128047958

012804795X

Advances in protein chemistry and structural biology ; volume 102

Front Cover; Personalized Medicine; Copyright; Contents; Contributors; Preface; Chapter One: High-Performance Affinity Chromatography: Applications in Drug-Protein Binding Studies and Personalized Medicine; 1. Introduction; 1.1. Drug-Protein Interactions in Blood; 1.2. Preparation of HPAC Columns for Drug-Protein Binding Studies; 2. Frontal Analysis Studies of Drug-Protein Interactions; 2.1. General Principles of Frontal Analysis; 2.2. Characterization of Simple Interactions by Frontal Analysis; 2.3. Characterization of Complex Interactions by Frontal Analysis

3. Zonal Elution Studies of Drug-Protein Interactions3.1. General Principles of Zonal Elution; 3.2. Characterization of Drug-Protein Interactions by Zonal Elution; 4. Other Methods for Examining Drug-Protein Interactions; 4.1. Peak Decay Method; 4.2. Ultrafast Affinity Extraction; 4.3. Chromatographic Immunoassays; 5. Conclusion; Acknowledgments; References; Chapter Two: Role of Proteomics in the Development of Personalized Medicine; 1. Introduction; 2. Protein Biomarkers; 2.1. Proteomic Technologies for Discovery of Biomarkers; 3. Protein Biochips

3.1. Role of Protein Biochips in Personalized Medicine3.2. Nanoproteomics; 4. Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine; 4.1. Integration of Diagnostics with Therapeutics; 5. Pharmacoproteomics; 5.1. Pharmacoproteomics and Personalized Medicine; 6. Concluding Remarks About Application of Proteomics for Personalized Medicine; References; Chapter Three: Metabolomics and Personalized Medicine; 1. Introduction; 2. The Value of ``Omics ́́Technologies in the Development of Personalized Medicine; 3. What is Metabolomics?

3.1. Analytical Methods Most Often Used for Metabolomics3.2. Statistical Approaches; 4. The Application of Metabolomics Toward Personalized Medicine; 4.1. Identification of Disease Biomarkers for Metabolomics-Based Diagnostics; 4.2. Pharmacometabonomics; 4.2.1. Metabolomics and the Elucidation of Drug Mechanisms; 4.2.2. Metabolomics and Understanding Response to Treatment; 4.2.3. Metabolomics and Understanding Drug Toxicology; 5. Concluding Remarks; Acknowledgments; References; Chapter Four: Clinical Perspectives on Targeting Therapies for Personalized Medicine; 1. Introduction

2. What Are Personalized Medicines?3. Rare Diseases; 4. Evidence for Precision Medicines from Real World Data; 5. Using ``Real World ́́Data; 6. Ethical Concerns; 7. Adaptive Trial Design; 8. Companion Diagnostics; 9. Biological Treatments; 10. Case Studies: Targets for Precision Medicines and Companion Diagnostics; 10.1. Drug Transporter Proteins; 10.2. Pleiotropic Effects of Statins; 10.3. Flecainide: Potential Off-Target Mechanism for Sudden Death; 10.4. EGF Receptor 2 Antagonism with Trastuzmab; 10.5. Diagnostic Markers to Guide Selection of Anti-cancer Tyrosine Kinase Receptor Inhibitors